The IFNβ treatment of multiple sclerosis (MS) in clinical practice: The experience at the MS Center of Bari, Italy

Neurological Sciences

Volumn 26, Issue SUPPL. 4, 2005, Pages

  Trojano, M ^a   Paolicelli, D ^a   Zimatore, G B ^a   De Robertis, F ^a   Fuiani, A ^a   Di Monte, E ^a   Livrea, P ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

IFN 1a; IFN 1b; Interferon beta; Multiple sclerosis; Phase IV trial

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD TOXICITY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; PHYSICAL DISABILITY; RATING SCALE; RELAPSE; CLINICAL TRIAL; COMPARATIVE STUDY; DISABILITY; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; COHORT STUDIES; DISABILITY EVALUATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 30644468000     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0511-9     Document Type: Article

References (13)

1. Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 342:1887-1892
2. Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13:227-231
3. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452
4. The IFNβ Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 43:655-661
5. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
6. The PRISMS Study Group (1998) Randomised doubleblind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
7. Seijo-Martinez M, Amigo MC, Arias M et al (2001) Experience of interferon beta (INF-β) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain). Mult Scler 7[Suppl 1]:54 (Abstract)
8. Öztekin N, Öztekin MF (2001) An open-label trial comparing the effects of IFNβ-1a (Rebif), (Avonex), and IFNβ-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: Results of 24 months of therapy. Mult Scler 7 [Suppl 1]:96 (Abstract)
9. Haas J, Firzlaff M, Schmidt M (2001) Comparison of new immunomodulatory treatments in the early stages of MS. Mult Scler 7[Suppl 1]:15 (Abstract)
10. Pakdaman H (2001) Response to beta-interferon in Iranian multiple sclerosis patients. Mult Scler 7[Suppl 1]:S54 (Abstract)
11. Miralles A, Fuentes B, Barreiro P, Diez-Tejedor E (2000) Comparative clinical efficacy analysis between interferon beta-1b and interferon beta-1a. Poster presented at 10th Annual Meeting of the European Neurological Society, June 21, 2000, Jerusalem, Israel
12. Trojano M, Liguori M, Paolicelli D et al (2003) An independent postmarketing study in southern Italy. Mult Scler 9:451-457
13. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878-1886